Alterity Therapeutics (PRNAD) Net Cash Flow (2009 - 2020)

Alterity Therapeutics (PRNAD) has reported Net Cash Flow for 9 consecutive years, with -$6.2 million the latest figure, recorded in Q2 2020.

• In Q2 2020, Net Cash Flow rose 36.76% year-over-year to -$6.2 million; the TTM figure through Dec 2021 stood at -$6.2 million (up 55.94% YoY), while the FY2025 annual figure was $13.3 million, up 692.99% from the prior year.
• Net Cash Flow came in at -$6.2 million for Q2 2020 at Alterity Therapeutics, down from $1.9 million in the prior quarter.
• The five-year high for Net Cash Flow was $1.9 million in Q4 2019, with the low at -$9.8 million in Q2 2019.
• Average Net Cash Flow over 5 years is -$3.4 million, with a median of -$4.4 million recorded in 2017.
• The largest YoY upside for Net Cash Flow was 137.95% in 2019 against a maximum downside of 20575.33% in 2019.
• Year by year, Net Cash Flow stood at -$598231.8 in 2016, then sank by 56.04% to -$933486.7 in 2017, then plunged by 444.27% to -$5.1 million in 2018, then surged by 137.95% to $1.9 million in 2019, then tumbled by 420.59% to -$6.2 million in 2020.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$6.2 million, $1.9 million, and -$9.8 million for Q2 2020, Q4 2019, and Q2 2019 respectively.